WO2006049442A1 - Pharmaceutical compositions for transdermal delivery - Google Patents
Pharmaceutical compositions for transdermal delivery Download PDFInfo
- Publication number
- WO2006049442A1 WO2006049442A1 PCT/KR2005/003698 KR2005003698W WO2006049442A1 WO 2006049442 A1 WO2006049442 A1 WO 2006049442A1 KR 2005003698 W KR2005003698 W KR 2005003698W WO 2006049442 A1 WO2006049442 A1 WO 2006049442A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ptd
- conjugate
- mtx
- amino acid
- acid sequence
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 20
- 230000037317 transdermal delivery Effects 0.000 title claims description 11
- 229960000485 methotrexate Drugs 0.000 claims abstract description 47
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims abstract description 45
- 230000000694 effects Effects 0.000 claims abstract description 27
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 230000026683 transduction Effects 0.000 claims abstract description 8
- 238000010361 transduction Methods 0.000 claims abstract description 8
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 12
- 235000018102 proteins Nutrition 0.000 claims description 11
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 210000004969 inflammatory cell Anatomy 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical group NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 4
- 229960002684 aminocaproic acid Drugs 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 235000009697 arginine Nutrition 0.000 claims description 3
- 150000001484 arginines Chemical class 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 239000000203 mixture Substances 0.000 abstract description 20
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 36
- 239000000126 substance Substances 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 23
- 210000003491 skin Anatomy 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 208000031648 Body Weight Changes Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000011888 autopsy Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000004579 body weight change Effects 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 231100000820 toxicity test Toxicity 0.000 description 4
- -1 (e.g. Substances 0.000 description 3
- IVYQODXBAVAAMS-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[[5-amino-2-[[2-[[2-[[6-amino-2-[[6-amino-2-[[2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoyl]amino] Chemical compound NC(N)=NCCCC(N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)NCC(O)=O IVYQODXBAVAAMS-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 238000011763 DBA/1J (JAX™ mouse strain) Methods 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010060891 General symptom Diseases 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 231100000668 minimum lethal dose Toxicity 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 231100000344 non-irritating Toxicity 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 2
- QUIGLPSHIFPEOV-CIUDSAMLSA-N Ala-Lys-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O QUIGLPSHIFPEOV-CIUDSAMLSA-N 0.000 description 2
- XPSGESXVBSQZPL-SRVKXCTJSA-N Arg-Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XPSGESXVBSQZPL-SRVKXCTJSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010015993 Eyelid oedema Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- LNLNHXIQPGKRJQ-SRVKXCTJSA-N Pro-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 LNLNHXIQPGKRJQ-SRVKXCTJSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 108010025153 lysyl-alanyl-alanine Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010061172 Gastrointestinal injury Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a novel pharmaceutical composition containing a conjugate of methotrexate and PTD (protein transduction domain) .
- methotrexate is widely known to inhibit the metabolism of folic acid necessary for the synthesis of DNA in cells and the growth and division of cells. Specifically, methotrexate inhibits the enzymatic activity of dihydrofolate reductase (DHFR), which is one of the enzymes involved in folic acid metabolism.
- DHFR dihydrofolate reductase
- methotrexate is a drug applicable to various diseases by inhibiting cell proliferation, which is effective against autoimmune diseases, such as rheumatoid arthritis and psoriasis, and shows a very fast effect that alleviates the symptoms of the diseases within about 2 weeks after administration.
- methotrexate is difficult to use for a long period of time, because side effects that cause serious liver toxicity, gastrointestinal disorders and injuries of the kidneys and hematopoietic organs have been continuously reported. Also, it is formulated mainly for oral or injection administration, but the oral administration of methotrexate involves significant inconvenience, such as administering the active drug in a dosage of 2.5 mg at 12-hr intervals three times weekly. For this reason, there has been a continued need for the development of a novel method for drug delivery that can increase the drug delivery efficiency of methotrexate to reduce the dosage thereof so as to minimize the side effects and that can eliminate the inconvenience of injection and oral administration.
- PTD protein transduction domain
- TAT protein transduction domain
- the present inventors have performed studies to develop PTD, and as a result, developed novel PTD that shows a significantly higher effect than the prior reported PTDs in delivering macromolecules (e.g., proteins) into cells in vitro and in vivo (see PCT/KR2003/000121 and PCT/KR2003/000122) .
- macromolecules e.g., proteins
- the present inventors prepared a conjugate of PTD and methotrexate for the effective local delivery of methotrexate, and applied a novel pharmaceutical composition for transdermal delivery containing the conjugate on the skin and observed the results.
- methotrexate was delivered to lesion sites through the epidermis to show pharmacological effects, thereby completing the present invention.
- FIG. 1 shows the preparation of a conjugate (MTX-PTD) of MTX (methotrexate) and PTD (protein transduction domain) by a peptide bond.
- FIG. 2 shows HPLC analysis results for the MTX-PTD conjugate according to the present invention.
- FIGS. 3 and 4 are confocal microphotographs showing the transdermal delivery of PTD used in the present invention.
- FIG. 5 is a graphic diagram showing the cell proliferation-inhibitory effect of the MTX-PTD conjugate according to the present invention.
- FIG. 6 is a graphic diagram showing a change in arthritis index caused by treatment with the MTX-PTD conjugate according to the present invention.
- FIG. 7 is a graphic diagram showing the levels of IL-4 and IFN- ⁇ in blood after treatment with the MTX-PTD conjugate according to the present invention.
- FIG. 8 is a graphic diagram showing the levels of IL- ⁇ and TNF- ⁇ in blood after treatment with the MTX-PTD conjugate according to the present invention.
- FIG. 9 is a graphic diagram showing the levels of RA factors in blood after treatment with the MTX-PTD conjugate according to the present invention.
- FIG. 10 is a photograph showing inflammatory tissues after treatment with the MTX-PTD conjugate according to the present invention.
- FIG. 11 is a graphic diagram showing the swelling inhibitory effect of the MTX-PTD conjugate in an animal model having TPA-induced inflammation.
- the present invention provides a conjugate of peptide PTD (protein transduction domain) and methotrexate (MTX) represented by Formula I.
- the inventive conjugate can be prepared by synthesizing PTD through a solid phase synthesis method and then linking the - COOH group of MTX to the N-terminal end of the synthesized PTD by a peptide bond (see FIG. 1) .
- the MTX-PTD conjugate according to the present invention is easily delivered into cells in lesion sites through the epidermis by virtue of the intracellular penetration and delivery effects of PTD, and the conjugate delivered into the cells is decomposed by intracellular protease, and as a result, the separated MTX shows pharmacological effects.
- PTD used in the present invention has a very excellent property of delivering proteins, peptides, chemical compounds and the like into the body through the skin, eyeball or airway, and thus if it is provided as a conjugate with MTX, it can deliver MTX into local sites in the body through various administration routes.
- MTX and PTD constituting the inventive conjugate can be linked to each other by various linkers, and particularly, by constructing a linker containing a region that is decomposed specifically by a certain enzyme, and it is possible to design the conjugate such that MTX can more effectively act in the desired local site.
- Linkers may vary depending on the purpose and direction of therapy, and in order to maximize effects in local sites, it is preferable to use linkers containing an - 0- or -S-S- bond, which are decomposed easily in cells. For the purpose of systemic effects, it is preferable to introduce a spacer linker containing a peptide bond.
- the PTD used in the present invention was developed by the present inventors and filed for patent. Namely, for use as PTD, each of the peptides set forth in SEQ ID NO: 1 and SEQ ID NO: 2 was prepared by a solid phase synthesis method. However, it can be understood that, according to the desired delivery sites and linkers used, other kinds of PTDs may also be used or peptides having at least 70% homology to the amino acid sequence of each of SEQ ID NO: 1 and SEQ ID NO: 2 may be used for the purpose of the present invention.
- the PTD used in the present invention consists preferably of 3-30 amino acids, at least 30% of which are arginines. Tyr Ala Arg VaI Arg Arg Arg GIy Pro Arg Arg (SEQ ID NO: D
- the outermost horny layer of the skin comprises a compact structure resulting from the natural death of keratinocytes, the main cells of the skin, and inhibits the penetration of foreign material and the evaporation of water. Also, it is in an acidic range of around pH 5 due to sweat and various lipids. In order to allow PTD to penetrate this horny layer, it should have a low molecular weight of 1,000 or less and a lipophilic property.
- the composition according to the present invention contains the MTX-PTD conjugate in an amount of 0.01-0.5% by weight based on the weight of the composition, together with a pharmaceutically acceptable carrier.
- the inventive composition comprises 3-5% by weight of ethanol, 5- 10% by weight of liquid paraffin, 30-40% by weight of Vaseline, 5-10% by weight of glycerin, 20-30% by weight of polyethylene glycol and 0.05-0.2% by weight of the MTX-PTD conjugate, all the amounts being based on the weight of the composition.
- One embodiment of the present invention suggests measurement results for the intracellular penetration effects of PTD used in the present invention. FITC-conjugated PTD was measured for fluorescent intensity, and as a result, it was observed that PTD very effectively delivered FITC into cells.
- a HeCaT cell line obtained from Department of Dermatology, College of Medicine, Chungnam National University, Korea
- MTX-ACA-PTD conjugate showed the highest inhibitory effect, followed by the MTX-PTD conjugate and the MTX alone in that order.
- the pharmacological effect of the MTX-ACA-PTD conjugate in arthritis animal models was measured.
- a group (M3) administered transdermally with an ointment containing MTX-ACA-PTD showed substantially the same effect as those of a group (M2) injected intraperitoneally (I. P.) with MTX-ACA-PTD and a group (Ml) injected intraperitoneally (I. P.) with MTX alone (see FIGS. 7, 8 and 9) .
- Measurement results for IL-4, IL- ⁇ and TNF- ⁇ levels and arthritis factor levels suggest that the MTX-ACA-PTD conjugate permeated the skin to effectively inhibit the activities of various inflammatory cells and immune cells.
- immune cells means T cells, B cells and the like.
- inflammatory cells means macrophages, eosinophils, neutorphils, basophils and the like.
- compositions according to the present invention can be formulated in various forms for oral or parenteral administration.
- Formulations for oral administration include, for example, tablets, pills, soft and hard capsules, liquids, suspensions, emulsions, syrups, granules and elixirs. These formulations may contain, in addition to the active ingredient, diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine), and lubricants, (e.g., silica, talc, stearic acid and a magnesium or calcium salt thereof, and/or polyethylene glycol) .
- diluents e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine
- lubricants e.g., silica, talc, stearic acid and a magnesium or
- Tablets may also contain binders, such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired, disintegrants, such as starches, agar, alginic acid or its sodium salt, and azeotropic mixtures; and/or absorbents, colorants, flavors, and sweeteners.
- the pharmaceutical composition containing the triptorelix-1 or its analogue as an active ingredient may be administered parenterally by subcutaneous, intravenous, intramuscular or intraperitoneal injection.
- the triptorelix-1 or its analogue may be mixed with a stabilizer or buffer in water to prepare a solution or suspension, which may then be provided as ampules or vials each containing a unit dosage form.
- the inventive pharmaceutical composition may be sterilized and/or may contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers.
- the composition may also contain other therapeutically effective substances.
- the composition can be formulated according to conventional mixing, granulating or coating methods .
- a fusion protein produced by fusing PTD (protein transduction domain) with the peptide may be used.
- PTD protein transduction domain
- Triptorelix-1 or its analogue as an active ingredient may be administered to mammals, including human beings, in a dosage of 0.01-500 mg/kg of bodyweight, and preferably 0.1-50 mg/kg of bodyweight, one time a day or in divided dosages, by oral or parenteral routes.
- the dosage of the active ingredient can be suitably selected depending on the age, sex or disease severity of a patient.
- PTD-MTX was synthesized through a solid phase synthesis method.
- peptides of SEQ ID NO: 1 For use as the peptide PTD, peptides of SEQ ID NO: 1
- MBHA resin obtained from Beadtech; cat. No. SHI-Bl ⁇
- DMF dimethylformamide
- piperidine a mixed solution of piperidine and DMF (50:50) for 15 minutes to remove Fmoc.
- 0.15 mmol of protected amino acids were mixed with 0.15 mmol of DIC (1,3- diisopropyl-cabodiimide) and 0.15 mmol of HOBt (N- hydroxybenzotriazole) in DMF solution, and the mixture was activated for 30 minutes and then mixed with the MBHA resin from which Fmoc was removed. Then, the mixture was allowed to react for about 4 hours and the above procedure was repeated three times.
- the peptide PTD has an ⁇ -helix structure. Therefore, when it is fused with MTX, MTX is unlikely to show effects due to steric hindrance effects caused by the three- dimensional structure of the peptide. For this reason, the present inventors solved this problem by introducing a linear linker capable of maintaining the structural distance between PTD and MTX.
- a linker used in the present invention was amino caproic acid (ACA) .
- ACA-PTD- resin was synthesized in the same manner as above and was treated in the same manner as the above synthesis of the PTD- MTX conjugate, thus synthesizing a PTD-ACA-MTX conjugate (see FIGS. 4 and 5; only a conjugate prepared using PTD of SEQ ID NO: 1 is shown in the drawings) .
- PTD was chemically fused with fluorescent FITC, delivered to the skin and measured for the degree of its delivery.
- FITC was prepared using amino caproic acid as a linker.
- the skin to be delivered with the PTD-FITC the skin of a 4- day-old pig having skin of an epidermal thickness similar to that of human skin was used.
- an ointment formulation was prepared by mixing
- Vaseline polyethylene glycol (8:2) .
- the back of the 4-day-old pig was shaved with a common razor, and the ointment formulation was applied evenly on a portion of the shaved back over an area of about 5 cm.
- a HeCaT cell line obtained from the Department of Dermatology, College of Medicine, Chungnam National University, Korea was used to analyze cell death. For this purpose, 1 x 10 6 cells/well were inoculated into DMEM medium
- MTX and PTD-ACA-MTX conjugates prepared in Example 1 were added with concentrations of 0.2, 1.5, 4.4, 13.3 and 40 ⁇ M respectively. After 2 days, the inhibition of proliferation of the cells was analyzed by the WST-I assay.
- tetrazolium salt is present in the respiratory chain of mitochondria and cleaved into a formazan dye by succinate-tetrazolium-reductase having activity only for viable cells, and if the number of viable cells increases, the entire activity of mitochondria dehydrogenase in a sample will increase. Since this increase in enzymatic activity induces an increase in the production of formazan dye, the formazan dye will show a linear correlation with the number of metabolically active cells in medium. The absorbance of the dye solution was measured with an ELISA reader to quantify the formazan dye produced by the metabolically active cells so as to observe cell proliferation ability and cell viability.
- mice obtained from Samtako
- e II-type collagen obtained from Sigma
- mice were divided into a group for intraperitoneal (I. P.) injection of the PTD- ACA-MTX conjugate prepared in Example 1, a group for transdermal administration of the PTD-ACA-MTX conjugate prepared in Example 1, and a group for intraperitoneal (I. P.) injection of MTX alone.
- I. P. intraperitoneal
- MTX was injected in a dosage of 0.3 mg/kg for 4 weeks, and for the group for transdermal administration, a cream-type composition consisting of 5 wt%, based on the weight of the composition, of ethanol, 15 wt% of liquid paraffin, 40 wt% of Vaseline, 0.1 wt% of the PTD-ACA- MTX conjugate, 10 wt% of glycerin and 30 wt% of polyethylene glycol was prepared and then applied on rheumatoid arthritis- induced sites four times weekly.
- FIGS. 7, 8 and 9 results obtained using PTD of SEQ ID NO: 2 are not shown in the drawings.
- N normal mice
- CT mice having rheumatoid arthritis induced by injection of collagen
- Ml the group injected intraperitoneally with MTX alone
- M2 the group injected intraperitoneally with PTD-ACA-MTX
- M3 the group for which the ointment preparation containing the PTD-ACA-MTX conjugate was administered transdermally.
- Normal DBA/1J represents a normal DBA/1J mouse obtained from Samtako
- CIA control represents a mouse having rheumatoid arthritis induced by injecting e II-type collagen
- Ml represents the group injected intraperitoneally with MTX alone
- M2 represents the group injected intraperitoneally with PTD-ACA-MTX
- M3 represents the group for which the ointment preparation containing PTD-ACA-MTX was administered transdermally.
- TPA (12-0- tetradecanoylphorbol-13-acetate; Alexis biochemical, San
- Toxicity by the single subcutaneous administration of PTD-ACA-MTX prepared in Example 1 was examined.
- Male and female Sprague Dawley rats (Samtako) were divided into an excipient control group administered with sterilized water for injection, and test groups administered with the inventive conjugate in amounts of 5, 50 and 500 mg/kg.
- Each of the animal groups consisted of 10 animals (five males and five females) and observed for mortality for 2 weeks, general symptoms, bodyweight change, and autopsy findings. All the test methods were performed according to toxicity test standards provided by the Korea Food and Drug Administration, and the test results are as follows. i) Animals being killed by the test substance were not observed throughout the test period.
- Example 7 Toxicity test by single subcutaneous administration to beagle dogs
- Toxicity caused by single subcutaneous administration of the inventive conjugate was examined.
- Male and female beagle dogs were administered subcutaneously with the inventive conjugate in each of amounts of 4, 20 and 100 mg/kg.
- Each of the animal groups consisted of four animals (2 males and 2 females) and observed for mortality for 2 weeks, general symptoms, bodyweight change, and autopsy findings. All the test methods were performed according to toxicity test standards provided by the Korea Food and Drug Administration, and the test results are as follows. i) No animal killed by the test substance was observed throughout the test period. ii) In the males and females of all the groups administered with more than 20 mg/kg of the conjugate, eyelid edema was observed during a period ranging from 1 hour to ⁇ hours after administration of the test substance.
- a reduction in spontaneous motility was observed starting from 1 hour after administration.
- edema and a reduction in spontaneous motility were continued up to 2 days after administration.
- anorexia was observed during a period ranging from 2 days to 4 days after administration, and diarrhea was observed 3 days after administration.
- bodyweight change in the male and female animals of the group administered with 100 mg/kg of the test substance, temporary inhibition of an increase in bodyweight, caused by the test substance, was observed 3 days after administration.
- the results of subcutaneous administration of the inventive conjugate to beagle dogs in the above test conditions were as follows: the males and females of the groups administered with more than 20 mg/kg of the test substance showed eyelid edema; the male of the group administered with 100 mg/kg showed a reduction in spontaneous motility, temporary anorexia and diarrhea; and the group administered with 100 mg/kg showed a spontaneous reduction in bodyweight at 3 days after the administration. From the above results, it was estimated that the minimum lethal dose by subcutaneous administration of the inventive conjugate would be over 100 mg/kg for both males and females.
- Example 8 Skin irritation test in rabbits The skin irritability of the inventive conjugate was examined. The inventive conjugate was applied to the healthy skin and scratch skin of New Zealand White rabbits, which were then evaluated comparatively with the healthy skin and scratch skin to which the inventive conjugate had not been applied. The results are as follows. i) Abnormal general symptoms by the application of the test substance were not observed. ii) An abnormal change in bodyweight caused by the application of the test substance was not observed. iii) Any abnormality in the normal and scratch sites was not observed throughout the observation period after the application of the test substance. iv) The evaluation result of skin irritability showed that the skin irritation index of the test substance was zero, indicating that the test substance is a non-irritating substance.
- the skin irritation index of the control substance was 0.17, indicating that it is a non-irritating substance .
- the results of the skin irritation test conducted on New Zealand White rabbits in the above test conditions indicate that the inventive conjugate is a non- irritating substance.
- the inventive pharmaceutical composition for transdermal delivery containing the methotrexate-PTD conjugate can be applied to the skin in a simple manner, such that it can effectively deliver methotrexate while minimizing side effects.
Abstract
The present invention relates to a pharmacutical composition for transdermal administration comprising a conjugate of methotrexate and PTD (protein transduction domain). In accordance with the present invention, the methotrexate, which is widely used for the treatment of psoriasis, rheumatoid and inflammation, etc., can be delivered transdermally to a local part of a patient body, in order to minimize the side effect of the methptrexate.
Description
PHARMACEUTICAL COMPOSITIONS FOR TRANSDERMAL DELIVERY
TECHNICAL FIELD
The present invention relates to a novel pharmaceutical composition containing a conjugate of methotrexate and PTD (protein transduction domain) .
BACKGROUND ART
In general, methotrexate is widely known to inhibit the metabolism of folic acid necessary for the synthesis of DNA in cells and the growth and division of cells. Specifically, methotrexate inhibits the enzymatic activity of dihydrofolate reductase (DHFR), which is one of the enzymes involved in folic acid metabolism. Thus, methotrexate is a drug applicable to various diseases by inhibiting cell proliferation, which is effective against autoimmune diseases, such as rheumatoid arthritis and psoriasis, and shows a very fast effect that alleviates the symptoms of the diseases within about 2 weeks after administration. However, methotrexate is difficult to use for a long period of time, because side effects that cause serious liver toxicity, gastrointestinal disorders and injuries of the kidneys and hematopoietic organs have been continuously reported. Also,
it is formulated mainly for oral or injection administration, but the oral administration of methotrexate involves significant inconvenience, such as administering the active drug in a dosage of 2.5 mg at 12-hr intervals three times weekly. For this reason, there has been a continued need for the development of a novel method for drug delivery that can increase the drug delivery efficiency of methotrexate to reduce the dosage thereof so as to minimize the side effects and that can eliminate the inconvenience of injection and oral administration.
Meanwhile, PTD (protein transduction domain) is a low- molecular-weight peptide used for the penetration of a physiologically active molecule into host cells, and a first reported PTD is TAT found in the surface protein of the HIV virus in the year 1998. This TAT PTD was reported to effectively deliver large-size proteins having a molecular weight of more than 120 kDa into cells within a short time. Since then, several PTD proteins of different amino acid sequences having functions similar to TAT PTD have been found and research for novel drug development and DDS studies using these peptides has been suggested. Accordingly, leading countries in the medical and pharmaceutical fields have made many efforts to find novel PTD and develop novel drugs using
the same. Also, the present inventors have performed studies to develop PTD, and as a result, developed novel PTD that shows a significantly higher effect than the prior reported PTDs in delivering macromolecules (e.g., proteins) into cells in vitro and in vivo (see PCT/KR2003/000121 and PCT/KR2003/000122) .
Thus, the present inventors prepared a conjugate of PTD and methotrexate for the effective local delivery of methotrexate, and applied a novel pharmaceutical composition for transdermal delivery containing the conjugate on the skin and observed the results. As a result, we surprisingly found that methotrexate was delivered to lesion sites through the epidermis to show pharmacological effects, thereby completing the present invention.
TECHNICAL PROBLEM
It is an object of the present invention to provide a novel pharmaceutical composition containing a conjugate of methotrexate and PTD. It is another object of the present invention to provide a method for locally administering methotrexate by transdermal delivery.
DESCRIPTION OF DRAWINGS
FIG. 1 shows the preparation of a conjugate (MTX-PTD) of MTX (methotrexate) and PTD (protein transduction domain) by a peptide bond. FIG. 2 shows HPLC analysis results for the MTX-PTD conjugate according to the present invention.
FIGS. 3 and 4 are confocal microphotographs showing the transdermal delivery of PTD used in the present invention.
FIG. 5 is a graphic diagram showing the cell proliferation-inhibitory effect of the MTX-PTD conjugate according to the present invention.
FIG. 6 is a graphic diagram showing a change in arthritis index caused by treatment with the MTX-PTD conjugate according to the present invention. FIG. 7 is a graphic diagram showing the levels of IL-4 and IFN-γ in blood after treatment with the MTX-PTD conjugate according to the present invention.
FIG. 8 is a graphic diagram showing the levels of IL-β and TNF-α in blood after treatment with the MTX-PTD conjugate according to the present invention.
FIG. 9 is a graphic diagram showing the levels of RA factors in blood after treatment with the MTX-PTD conjugate according to the present invention.
FIG. 10 is a photograph showing inflammatory tissues after treatment with the MTX-PTD conjugate according to the present invention.
FIG. 11 is a graphic diagram showing the swelling inhibitory effect of the MTX-PTD conjugate in an animal model having TPA-induced inflammation.
MODE FOR INVENTION
To achieve the above objects, the present invention provides a conjugate of peptide PTD (protein transduction domain) and methotrexate (MTX) represented by Formula I. The inventive conjugate can be prepared by synthesizing PTD through a solid phase synthesis method and then linking the - COOH group of MTX to the N-terminal end of the synthesized PTD by a peptide bond (see FIG. 1) . [Formula I]
The MTX-PTD conjugate according to the present invention is easily delivered into cells in lesion sites through the
epidermis by virtue of the intracellular penetration and delivery effects of PTD, and the conjugate delivered into the cells is decomposed by intracellular protease, and as a result, the separated MTX shows pharmacological effects. PTD used in the present invention has a very excellent property of delivering proteins, peptides, chemical compounds and the like into the body through the skin, eyeball or airway, and thus if it is provided as a conjugate with MTX, it can deliver MTX into local sites in the body through various administration routes. Also, MTX and PTD constituting the inventive conjugate can be linked to each other by various linkers, and particularly, by constructing a linker containing a region that is decomposed specifically by a certain enzyme, and it is possible to design the conjugate such that MTX can more effectively act in the desired local site. Linkers may vary depending on the purpose and direction of therapy, and in order to maximize effects in local sites, it is preferable to use linkers containing an - 0- or -S-S- bond, which are decomposed easily in cells. For the purpose of systemic effects, it is preferable to introduce a spacer linker containing a peptide bond.
The PTD used in the present invention was developed by the present inventors and filed for patent. Namely, for use
as PTD, each of the peptides set forth in SEQ ID NO: 1 and SEQ ID NO: 2 was prepared by a solid phase synthesis method. However, it can be understood that, according to the desired delivery sites and linkers used, other kinds of PTDs may also be used or peptides having at least 70% homology to the amino acid sequence of each of SEQ ID NO: 1 and SEQ ID NO: 2 may be used for the purpose of the present invention. The PTD used in the present invention consists preferably of 3-30 amino acids, at least 30% of which are arginines. Tyr Ala Arg VaI Arg Arg Arg GIy Pro Arg Arg (SEQ ID NO: D
Ala Lys Ala Ala Arg GIn Ala Ala Arg (SEQ ID NO: 2) In the delivery of drugs through the skin, there are various limitations in view of the structural and physical properties of the skin. Particularly, the outermost horny layer of the skin comprises a compact structure resulting from the natural death of keratinocytes, the main cells of the skin, and inhibits the penetration of foreign material and the evaporation of water. Also, it is in an acidic range of around pH 5 due to sweat and various lipids. In order to allow PTD to penetrate this horny layer, it should have a low molecular weight of 1,000 or less and a lipophilic property. The composition according to the present invention
contains the MTX-PTD conjugate in an amount of 0.01-0.5% by weight based on the weight of the composition, together with a pharmaceutically acceptable carrier. Preferably, the inventive composition comprises 3-5% by weight of ethanol, 5- 10% by weight of liquid paraffin, 30-40% by weight of Vaseline, 5-10% by weight of glycerin, 20-30% by weight of polyethylene glycol and 0.05-0.2% by weight of the MTX-PTD conjugate, all the amounts being based on the weight of the composition. One embodiment of the present invention suggests measurement results for the intracellular penetration effects of PTD used in the present invention. FITC-conjugated PTD was measured for fluorescent intensity, and as a result, it was observed that PTD very effectively delivered FITC into cells.
In another embodiment of the present invention, a HeCaT cell line (obtained from Department of Dermatology, College of Medicine, Chungnam National University, Korea) was used to analyze the cell proliferation inhibitory effect of each of MTX alone, a MTX-PTD conjugate and a MTX-ACA-PTD conjugate. As a result, the MTX-ACA-PTD conjugate showed the highest inhibitory effect, followed by the MTX-PTD conjugate and the MTX alone in that order.
In still another embodiment of the present invention, the pharmacological effect of the MTX-ACA-PTD conjugate in arthritis animal models was measured. As a result, it was observed that a group (M3) administered transdermally with an ointment containing MTX-ACA-PTD showed substantially the same effect as those of a group (M2) injected intraperitoneally (I. P.) with MTX-ACA-PTD and a group (Ml) injected intraperitoneally (I. P.) with MTX alone (see FIGS. 7, 8 and 9) . Measurement results for IL-4, IL-β and TNF-α levels and arthritis factor levels suggest that the MTX-ACA-PTD conjugate permeated the skin to effectively inhibit the activities of various inflammatory cells and immune cells.
As used herein, the term "immune cells" means T cells, B cells and the like. As used herein, the term "inflammatory cells" means macrophages, eosinophils, neutorphils, basophils and the like.
The pharmaceutical composition according to the present invention can be formulated in various forms for oral or parenteral administration. Formulations for oral administration include, for example, tablets, pills, soft and hard capsules, liquids, suspensions, emulsions, syrups, granules and elixirs. These formulations may contain, in
addition to the active ingredient, diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine), and lubricants, (e.g., silica, talc, stearic acid and a magnesium or calcium salt thereof, and/or polyethylene glycol) . Tablets may also contain binders, such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired, disintegrants, such as starches, agar, alginic acid or its sodium salt, and azeotropic mixtures; and/or absorbents, colorants, flavors, and sweeteners.
The pharmaceutical composition containing the triptorelix-1 or its analogue as an active ingredient may be administered parenterally by subcutaneous, intravenous, intramuscular or intraperitoneal injection. For parenteral administration, the triptorelix-1 or its analogue may be mixed with a stabilizer or buffer in water to prepare a solution or suspension, which may then be provided as ampules or vials each containing a unit dosage form. The inventive pharmaceutical composition may be sterilized and/or may contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or
buffers. In addition, the composition may also contain other therapeutically effective substances. The composition can be formulated according to conventional mixing, granulating or coating methods . In order to introduce the inventive peptide into cells, a fusion protein produced by fusing PTD (protein transduction domain) with the peptide may be used. As the protein transduction domain (PTD), any PTD known in the art may be used. Triptorelix-1 or its analogue as an active ingredient may be administered to mammals, including human beings, in a dosage of 0.01-500 mg/kg of bodyweight, and preferably 0.1-50 mg/kg of bodyweight, one time a day or in divided dosages, by oral or parenteral routes. The dosage of the active ingredient can be suitably selected depending on the age, sex or disease severity of a patient.
Hereinafter, the present invention will be described in detail by examples. It is to be understood, however, that these examples are for illustrative purpose only and are not construed to limit the scope of the present invention.
EXAMPLES
Example 1: Synthesis of PTD-MTX
PTD-MTX was synthesized through a solid phase synthesis method. For use as the peptide PTD, peptides of SEQ ID NO: 1
(Tyr Ala Arg VaI Arg Arg Arg GIy Pro Arg Arg) or SEQ ID NO: 2 (Ala Lys Ala Ala Arg GIn Ala Ala Arg) were prepared and used in tests. Amino acid residues that can cause side reactions during the synthesis reaction were protected before the PTD synthesis. Since side chains, such as A (alanine), V
(valine) , G (glycine) and P (proline) , have no reactivity, a product was protected with Fmoc (fluorenylmethoxy carbonyl) only at NH2, and since R (arginine) , Y (tyrosine) and K
(lysine) have no side-chain reactivity, they were protected with Pmc (2, 2, 5, 7, 8-pentamethylchroman-6-sulfonyl) and tBU
(t-butyl) , respectively. As in the above products, NH2 was protected with Fmoc (fluorenylmethoxy carbonyl) . 0.1 mmol
MBHA resin (obtained from Beadtech; cat. No. SHI-Blβ) was swollen in DMF (dimethylformamide) for 15 minutes and treated two times with a mixed solution of piperidine and DMF (50:50) for 15 minutes to remove Fmoc. Meanwhile, 0.15 mmol of protected amino acids were mixed with 0.15 mmol of DIC (1,3- diisopropyl-cabodiimide) and 0.15 mmol of HOBt (N- hydroxybenzotriazole) in DMF solution, and the mixture was activated for 30 minutes and then mixed with the MBHA resin
from which Fmoc was removed. Then, the mixture was allowed to react for about 4 hours and the above procedure was repeated three times. The reaction was repeated to synthesize a peptide of PTD-resin. Next, MTX (0.15 iranol) was mixed with 0.15 mmol PyBOP (benzotriazole-1-yl-oxy-tris- pyrrolidino-phophoniumhexafluorophosphate) and 0.15 mmol HOBt
(N-hydroxybenzotriazole) in DMF solution, and the mixture was activated for 30 minutes and mixed with the above PTD-resin, followed by reaction for 4 hours. Finally, the reaction product was allowed to react with a solution of TFA:H20:EDT:thioanisole:phenol = 8.25:0.5:0.25:0.25:0.75 for 24 hours so as to remove the respective amino acid-protecting groups and the resin. The resulting material was isolated and purified by HPLC and its weight measured. Then, the MTX- PTD conjugate isolated and purified by HPLC was lyophilized, thus obtaining the desired product.
Meanwhile, the peptide PTD has an α-helix structure. Therefore, when it is fused with MTX, MTX is unlikely to show effects due to steric hindrance effects caused by the three- dimensional structure of the peptide. For this reason, the present inventors solved this problem by introducing a linear linker capable of maintaining the structural distance between PTD and MTX. A linker used in the present invention was
amino caproic acid (ACA) . In solid phase synthesis, ACA-PTD- resin was synthesized in the same manner as above and was treated in the same manner as the above synthesis of the PTD- MTX conjugate, thus synthesizing a PTD-ACA-MTX conjugate (see FIGS. 4 and 5; only a conjugate prepared using PTD of SEQ ID NO: 1 is shown in the drawings) .
Example 2 : Transdermal delivery effects
To measure the transdermal delivery effect of PTD, PTD was chemically fused with fluorescent FITC, delivered to the skin and measured for the degree of its delivery. The PTD-
FITC was prepared using amino caproic acid as a linker. As the skin to be delivered with the PTD-FITC, the skin of a 4- day-old pig having skin of an epidermal thickness similar to that of human skin was used. For use in the transdermal delivery test, an ointment formulation was prepared by mixing
10 mM PTD-FITC with a cream-type composition consisting of
Vaseline:polyethylene glycol (8:2) .
The back of the 4-day-old pig was shaved with a common razor, and the ointment formulation was applied evenly on a portion of the shaved back over an area of about 5 cm. After
2 hours, the pig was sacrificed and the skin was removed, freeze-sectioned and then observed with a confocal microscope
to analyze the transfermal delivery efficiency of PTD. The observation results showed that PTD was delivered not only to the epidermis, but also to the dermis. This suggests the possibility of transdermal drug delivery (see FIG. 5; PTD of SEQ ID NO: 2 is not shown in the drawing) .
Example 3: Effect of PTD-MTX in vitro
In this Example, the cell proliferation-inhibitory effect of PTD-MTX was observed by WST-I assay (Roche Biochemical) in vitro.
To analyze the cell proliferation-inhibitory effect of PTD-MTX, a HeCaT cell line (obtained from the Department of Dermatology, College of Medicine, Chungnam National University, Korea) was used to analyze cell death. For this purpose, 1 x 106 cells/well were inoculated into DMEM medium
(10% FCS, antibiotics (GIBCO)) on a 96-well plate and cultured overnight. To the culture medium, MTX alone, PTD-
MTX and PTD-ACA-MTX conjugates prepared in Example 1 were added with concentrations of 0.2, 1.5, 4.4, 13.3 and 40 μM respectively. After 2 days, the inhibition of proliferation of the cells was analyzed by the WST-I assay.
In the WST-I assay, tetrazolium salt is present in the respiratory chain of mitochondria and cleaved into a formazan
dye by succinate-tetrazolium-reductase having activity only for viable cells, and if the number of viable cells increases, the entire activity of mitochondria dehydrogenase in a sample will increase. Since this increase in enzymatic activity induces an increase in the production of formazan dye, the formazan dye will show a linear correlation with the number of metabolically active cells in medium. The absorbance of the dye solution was measured with an ELISA reader to quantify the formazan dye produced by the metabolically active cells so as to observe cell proliferation ability and cell viability.
The test results showed that the cell proliferation- inhibitory effect was in the order of MTX alone < PTD-MTX < PTD-ACA-MTX. These results contrary to the prior enzyme test results that the PTD-MTX conjugate shows low effects compared to MTX alone are believed to be because: i) the intracellular delivery effect of MTD is promoted by PTD; and ii) the steric hindrance effect of PTD is removed by the intracellular metabolism of PTD. Also, it is believed that, since the MTX- PTD conjugate prepared in the present invention conserves the active site of MTX, the steric hindrance effect of PTD is disregarded (see FIG. 6; PTD of SEQ ID NO: 2 is not shown in the drawing) .
Example 4: Effect of PTD-ACA-MTX in arthritis animal model
For in vivo verification of the pharmacological effects of the PTD-ACA-MTX conjugate, DBA/1J mice (obtained from Samtako) were injected with e II-type collagen (obtained from Sigma) to induce rheumatoid arthritis. The mice were divided into a group for intraperitoneal (I. P.) injection of the PTD- ACA-MTX conjugate prepared in Example 1, a group for transdermal administration of the PTD-ACA-MTX conjugate prepared in Example 1, and a group for intraperitoneal (I. P.) injection of MTX alone. For the groups for intraperitoneal
(I. P.) injection, MTX was injected in a dosage of 0.3 mg/kg for 4 weeks, and for the group for transdermal administration, a cream-type composition consisting of 5 wt%, based on the weight of the composition, of ethanol, 15 wt% of liquid paraffin, 40 wt% of Vaseline, 0.1 wt% of the PTD-ACA- MTX conjugate, 10 wt% of glycerin and 30 wt% of polyethylene glycol was prepared and then applied on rheumatoid arthritis- induced sites four times weekly. After treatment with the drugs, the arthritis index was monitored one time each week, and after 4 weeks, the animals were sacrificed and the IL-4, IL-β, TNF-α and arthritis factor levels in the blood were
measured (see FIGS. 7, 8 and 9; results obtained using PTD of SEQ ID NO: 2 are not shown in the drawings) . In FIGS. 7, 8 and 9, N: normal mice; CT: mice having rheumatoid arthritis induced by injection of collagen; Ml: the group injected intraperitoneally with MTX alone; M2 : the group injected intraperitoneally with PTD-ACA-MTX; and M3 : the group for which the ointment preparation containing the PTD-ACA-MTX conjugate was administered transdermally.
As a result, it was observed that the amount of inflammation-mediating cytokine, such as TNF-α, which is most important in rheumatoid arthritis, was greatly decreased. Also, it was confirmed in tissue photographs that inflammatory cells, which have penetrated inflammatory sites, were greatly decreased as a result of treatment with the drug. This suggests that the PTD-ACA-MTX conjugate permeated the skin to effectively inhibit the activities of various inflammatory cells and immune cells (see FIG. 8; results obtained using PTD of SEQ ID NO: 2 are not shown in the drawing) . In FIG. 8, the upper photographs show the results of H&E staining, the lower photographs show the results of M- T staining, Normal DBA/1J represents a normal DBA/1J mouse obtained from Samtako, CIA control represents a mouse having rheumatoid arthritis induced by injecting e II-type collagen,
Ml represents the group injected intraperitoneally with MTX alone, M2 represents the group injected intraperitoneally with PTD-ACA-MTX, and M3 represents the group for which the ointment preparation containing PTD-ACA-MTX was administered transdermally.
Example 5: Effect of PTD-ACA-MTX in inflammatory disease model
To confirm therapeutic effects against psoriasis, the PTD-ACA-MTX conjugate prepared in Example 1 was analyzed for its therapeutic effect against skin inflammation. TPA (12-0- tetradecanoylphorbol-13-acetate; Alexis biochemical, San
Diego) was applied to the ear of an ICR mouse (obtained from
Samtako) once a day for 3 days to induce skin inflammation. 5 days after the start of the experiment, the thickness of the ear was measured with a micrometer screw, and the swollen thickness was calculated and used as an index of chronic edema. Also, the ear was punched and inflammatory cells in the inflammatory site were analyzed. A composition for transdermal delivery containing the PTD-ACA-MTX conjugate was applied to the ear skin. The composition was prepared in the same manner as in the example described above, and applied once a day for 10 days (see FIG. 11) .
Example 6: Toxicity test by single subcutaneous administration to rats
Toxicity by the single subcutaneous administration of PTD-ACA-MTX prepared in Example 1 was examined. Male and female Sprague Dawley rats (Samtako) were divided into an excipient control group administered with sterilized water for injection, and test groups administered with the inventive conjugate in amounts of 5, 50 and 500 mg/kg. Each of the animal groups consisted of 10 animals (five males and five females) and observed for mortality for 2 weeks, general symptoms, bodyweight change, and autopsy findings. All the test methods were performed according to toxicity test standards provided by the Korea Food and Drug Administration, and the test results are as follows. i) Animals being killed by the test substance were not observed throughout the test period. ii) In the male and female animals of the group administered with 500 mg/kg of the test substance, congestion was observed starting from one day after the administration, and incrustation was observed starting from 2 days after the administration. In the male animals of the group administered with 500 mg/kg of the test substance, even
systemic edema was observed. Diarrhea and soft feces were sporadically observed during a period ranging from 4 days to 6 days after the administration. iii) Regarding bodyweight change, in the male animals of the group administered with 500 mg/kg of the test substance, the inhibition of an increase in bodyweight, caused by by the test substance, was observed at 3 days, 7 days and 14 days after administration. iv) Regarding autopsy findings, in the male and female animals of the group administered with 500 mg/kg of the test substance, red fluid retention and incrustation caused by the test material were observed at the administration site. In the female animals, splenomegaly was observed.
From the above results, it was estimated that subcutaneous administration of the inventive conjugate to rats in the above test conditions would show a minimum lethal dose (MLD) of more than 500 mg/kg in the case of the group administered with 500 mg/kg of the test substance.
Example 7: Toxicity test by single subcutaneous administration to beagle dogs
Toxicity caused by single subcutaneous administration of the inventive conjugate was examined. Male and female beagle
dogs were administered subcutaneously with the inventive conjugate in each of amounts of 4, 20 and 100 mg/kg. Each of the animal groups consisted of four animals (2 males and 2 females) and observed for mortality for 2 weeks, general symptoms, bodyweight change, and autopsy findings. All the test methods were performed according to toxicity test standards provided by the Korea Food and Drug Administration, and the test results are as follows. i) No animal killed by the test substance was observed throughout the test period. ii) In the males and females of all the groups administered with more than 20 mg/kg of the conjugate, eyelid edema was observed during a period ranging from 1 hour to β hours after administration of the test substance. In one male and female of the group administered with 100 mg/kg of the test substance, a reduction in spontaneous motility was observed starting from 1 hour after administration. In one male of the group administered with 20 mg/kg of the test substance and one female of the group administered with 100 mg/kg of the test substance, edema and a reduction in spontaneous motility were continued up to 2 days after administration. In the males of the group administered with 100 mg/kg of the test substance, anorexia was observed during
a period ranging from 2 days to 4 days after administration, and diarrhea was observed 3 days after administration. iii) Regarding bodyweight change, in the male and female animals of the group administered with 100 mg/kg of the test substance, temporary inhibition of an increase in bodyweight, caused by the test substance, was observed 3 days after administration. iv) Regarding autopsy, abnormal findings were not observed. In summary, the results of subcutaneous administration of the inventive conjugate to beagle dogs in the above test conditions were as follows: the males and females of the groups administered with more than 20 mg/kg of the test substance showed eyelid edema; the male of the group administered with 100 mg/kg showed a reduction in spontaneous motility, temporary anorexia and diarrhea; and the group administered with 100 mg/kg showed a spontaneous reduction in bodyweight at 3 days after the administration. From the above results, it was estimated that the minimum lethal dose by subcutaneous administration of the inventive conjugate would be over 100 mg/kg for both males and females.
Example 8 : Skin irritation test in rabbits
The skin irritability of the inventive conjugate was examined. The inventive conjugate was applied to the healthy skin and scratch skin of New Zealand White rabbits, which were then evaluated comparatively with the healthy skin and scratch skin to which the inventive conjugate had not been applied. The results are as follows. i) Abnormal general symptoms by the application of the test substance were not observed. ii) An abnormal change in bodyweight caused by the application of the test substance was not observed. iii) Any abnormality in the normal and scratch sites was not observed throughout the observation period after the application of the test substance. iv) The evaluation result of skin irritability showed that the skin irritation index of the test substance was zero, indicating that the test substance is a non-irritating substance. The skin irritation index of the control substance was 0.17, indicating that it is a non-irritating substance . In summary, the results of the skin irritation test conducted on New Zealand White rabbits in the above test conditions indicate that the inventive conjugate is a non- irritating substance.
INDUSTRIAL APPLICABILITY
As described above, the inventive pharmaceutical composition for transdermal delivery containing the methotrexate-PTD conjugate can be applied to the skin in a simple manner, such that it can effectively deliver methotrexate while minimizing side effects.
Claims
1. A transdermal pharmaceutical composition for the treatment of autoimmune disease, comprising 0.01-0.5 wt% of a conjugate of methotrexate and PTD (protein transduction domain), together with excipients.
2. The transdermal pharmaceutical composition of Claim 1, wherein the PTD is a peptide comprising an amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 70% homology to the amino acid sequence of SEQ ID NO:
1.
3. The transdermal pharmaceutical composition of Claim 1, wherein the PTD is a peptide comprising an amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 70% homology to the amino acid sequence of SEQ ID NO: 2.
4. The transdermal pharmaceutical composition of Claim 1, wherein the PTD consists of 5-30 amino acids, at least 30% of which are arginines.
5. The transdermal pharmaceutical composition of any one of Claims 1 to 4, wherein the PTD and the methotrexate are linked to each other by a direct covalent bond, a peptide bond or a linker.
6. The transdermal pharmaceutical composition of Claim 5, wherein the linker comprises an -0- or -S-S- bond.
7. The transdermal pharmaceutical composition of Claim 6, wherein the linker is amino caproic acid.
8. The transdermal pharmaceutical composition of Claims 1 to 4, wherein the autoimmune disease is psoriasis or rheumatoid arthritis.
9. The transdermal pharmaceutical composition of Claim 5, wherein the autoimmune disease is psoriasis or rheumatoid arthritis .
10. The transdermal pharmaceutical composition of Claim 6 or 7, wherein the autoimmune disease is psoriasis or rheumatoid arthritis.
11. A method for transdermally delivering methotrexate, comprising applying the pharmaceutical composition of Claim 1 to the skin of a patient in need thereof.
12. A conjugate of methotrexate and PTD for inhibiting the activities of immune cells and inflammatory cells by transdermal delivery.
13. The conjugate of Claim 12, wherein the PTD is a peptide comprising an amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 70% homology to the amino acid sequence of SEQ ID NO: 1.
14. The conjugate of Claim 12, wherein the PTD is a peptide comprising an amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 70% homology to the amino acid sequence of SEQ ID NO: 2.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2005800372234A CN101072566B (en) | 2004-11-03 | 2005-11-03 | Pharmaceutical compositions for transdermal delivery |
| JP2007540252A JP4933440B2 (en) | 2004-11-03 | 2005-11-03 | Pharmaceutical composition for transdermal delivery |
| EP05820534A EP1809291A4 (en) | 2004-11-03 | 2005-11-03 | Pharmaceutical compositions for transdermal delivery |
| US11/667,185 US8067376B2 (en) | 2004-11-03 | 2005-11-03 | Pharmaceutical compositions for transdermal delivery |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20040088762 | 2004-11-03 | ||
| KR10-2004-0088762 | 2004-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006049442A1 true WO2006049442A1 (en) | 2006-05-11 |
Family
ID=36319411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2005/003698 WO2006049442A1 (en) | 2004-11-03 | 2005-11-03 | Pharmaceutical compositions for transdermal delivery |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8067376B2 (en) |
| EP (1) | EP1809291A4 (en) |
| JP (1) | JP4933440B2 (en) |
| KR (1) | KR100897915B1 (en) |
| CN (1) | CN101072566B (en) |
| WO (1) | WO2006049442A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102274165A (en) * | 2010-06-13 | 2011-12-14 | 赵宁 | Ointment based on anti-TNF-alpha monoclonal antibody used for treating psoriasis |
| EP2576594A1 (en) * | 2010-05-30 | 2013-04-10 | The Governing Council Of The University Of Toronto | Mitochondrial penetrating peptides as carriers for antimicrobials |
| US9867827B1 (en) | 2015-08-27 | 2018-01-16 | Florida A&M University | Methods and formulations for topical treatment of psoriasis |
| EP3613437A4 (en) * | 2017-05-11 | 2020-05-27 | Caregen Co., Ltd. | Methotrexate and peptide binder |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8354116B2 (en) * | 2007-06-18 | 2013-01-15 | Biochemics, Inc. | Bifunctional synthetic molecules |
| KR101746757B1 (en) * | 2009-01-24 | 2017-06-13 | 아미놉테린 엘엘씨. | Pharmaceutical composition comprising racemic aminopterin |
| KR101597672B1 (en) * | 2009-03-20 | 2016-02-25 | 앤태어스 파머, 인코퍼레이티드 | Hazardous agent injection system |
| JP5976815B2 (en) * | 2011-09-23 | 2016-08-24 | ヴェストファーリッシュ ヴィルヘルム−ユニバーシテート ミュンスター | Yersinia external protein M (YopM) in the treatment of psoriasis |
| AU2015223035A1 (en) | 2014-02-26 | 2016-09-22 | Luma Therapeutics, Inc. | Ultraviolet phototherapy apparatuses and methods |
| JP2019511343A (en) | 2016-02-09 | 2019-04-25 | ルマ セラピューティクス，インク．Ｌｕｍａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Methods, compositions and devices for treating psoriasis with phototherapy |
| US11369695B2 (en) * | 2016-12-05 | 2022-06-28 | The Jackson Laboratory | Fat droplets in retina and optic nerve as a diagnostic marker for neurodegeneration and glaucoma in humans |
| CN112094317B (en) * | 2019-06-18 | 2022-04-22 | 首都医科大学 | His-Gly-Lys modified methotrexate, synthesis, anti-transfer activity and application thereof |
| KR20220124921A (en) | 2021-03-04 | 2022-09-14 | (주)쎌트로이 | Methotrexate conjugate compound and composition for transdermal administration comprising the same |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6485740B1 (en) * | 2000-03-14 | 2002-11-26 | Yutoku Pharmaceutical Ind., Co., Ltd. | Transdermal methotrexate preparations |
| WO2003059940A1 (en) * | 2002-01-19 | 2003-07-24 | Forhumantech. Co., Ltd. | Biomolecule transduction motif sim-2-btm and the use thereof |
| WO2003059941A1 (en) * | 2002-01-19 | 2003-07-24 | Forhumantech. Co., Ltd | Biomolecule transduction motif mph-1-btm and the use thereof |
| WO2004013160A2 (en) * | 2002-08-05 | 2004-02-12 | University Of Rochester | Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2808492A (en) * | 1991-10-26 | 1993-05-21 | East Riding Laboratories Limited | Medicament composition for topical application |
| ATE419273T1 (en) | 1998-11-13 | 2009-01-15 | Cyclacel Ltd | TRANSLOCATION VECTORS DERIVED FROM THE ANTENNAPEDIA HOMEODOMAIN HELIX 3 |
| AU772074B2 (en) * | 1999-04-28 | 2004-04-08 | Vectramed, Inc. | Enzymatically activated polymeric drug conjugates |
| US20020009491A1 (en) * | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| KR100439204B1 (en) * | 2000-10-25 | 2004-07-07 | 주식회사 삼양사 | Composition for transdermal delivery of methotrexate |
| FR2830016B1 (en) * | 2001-09-27 | 2004-06-25 | Synt Em | COMPOSITIONS FOR THE VECTORIZATION OF TAXOID DERIVATIVES THROUGH THE HEMATOENCEPHALIC BARRIER AND THEIR USE FOR THE TREATMENT OF CANCERS, PARTICULARLY BRAIN CANCERS |
| CN102133407A (en) | 2002-03-01 | 2011-07-27 | 图兰恩教育基金管理人 | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
| SE0201863D0 (en) * | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| CN1234707C (en) * | 2003-03-24 | 2006-01-04 | 中国药科大学 | Anti-cancer chemicals of methotrexate derivatives and their uses in pharmaceutical science |
-
2005
- 2005-11-03 US US11/667,185 patent/US8067376B2/en not_active Expired - Fee Related
- 2005-11-03 EP EP05820534A patent/EP1809291A4/en not_active Withdrawn
- 2005-11-03 WO PCT/KR2005/003698 patent/WO2006049442A1/en active Application Filing
- 2005-11-03 CN CN2005800372234A patent/CN101072566B/en not_active Expired - Fee Related
- 2005-11-03 KR KR1020077009791A patent/KR100897915B1/en active IP Right Grant
- 2005-11-03 JP JP2007540252A patent/JP4933440B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6485740B1 (en) * | 2000-03-14 | 2002-11-26 | Yutoku Pharmaceutical Ind., Co., Ltd. | Transdermal methotrexate preparations |
| WO2003059940A1 (en) * | 2002-01-19 | 2003-07-24 | Forhumantech. Co., Ltd. | Biomolecule transduction motif sim-2-btm and the use thereof |
| WO2003059941A1 (en) * | 2002-01-19 | 2003-07-24 | Forhumantech. Co., Ltd | Biomolecule transduction motif mph-1-btm and the use thereof |
| WO2004013160A2 (en) * | 2002-08-05 | 2004-02-12 | University Of Rochester | Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
Non-Patent Citations (3)
| Title |
|---|
| ALVAREZ-FIGUEROA ET AL: "Passive and iontophoretic transdermal penetration of methotrexate.", INT J PHARM., vol. 212, no. 1, 2001, pages 101 - 107, XP008122550 * |
| ALVAREZ-FIGUEROA ET AL: "Transdermal delivery of methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsions.", INTERNATIONAL JOURNAL OF PHARMACEUTICS., vol. 215, no. 1-2, 2001, pages 57 - 65, XP008122480 * |
| See also references of EP1809291A4 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2576594A1 (en) * | 2010-05-30 | 2013-04-10 | The Governing Council Of The University Of Toronto | Mitochondrial penetrating peptides as carriers for antimicrobials |
| EP2576594A4 (en) * | 2010-05-30 | 2013-11-06 | Univ Toronto | Mitochondrial penetrating peptides as carriers for antimicrobials |
| US9173952B2 (en) | 2010-05-30 | 2015-11-03 | The Governing Council Of The University Of Toronto | Mitochondrial penetrating peptides as carriers for antimicrobials |
| CN102274165A (en) * | 2010-06-13 | 2011-12-14 | 赵宁 | Ointment based on anti-TNF-alpha monoclonal antibody used for treating psoriasis |
| CN102274165B (en) * | 2010-06-13 | 2012-11-21 | 赵宁 | Ointment based on anti-TNF-alpha monoclonal antibody used for treating psoriasis |
| US9867827B1 (en) | 2015-08-27 | 2018-01-16 | Florida A&M University | Methods and formulations for topical treatment of psoriasis |
| EP3613437A4 (en) * | 2017-05-11 | 2020-05-27 | Caregen Co., Ltd. | Methotrexate and peptide binder |
| US11253604B2 (en) | 2017-05-11 | 2022-02-22 | Caregen Co., Ltd. | Conjugate of methotrexate and peptide |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1809291A1 (en) | 2007-07-25 |
| JP2008519068A (en) | 2008-06-05 |
| CN101072566B (en) | 2012-05-16 |
| JP4933440B2 (en) | 2012-05-16 |
| US20080306075A1 (en) | 2008-12-11 |
| KR20070083862A (en) | 2007-08-24 |
| US8067376B2 (en) | 2011-11-29 |
| KR100897915B1 (en) | 2009-05-18 |
| EP1809291A4 (en) | 2012-04-04 |
| CN101072566A (en) | 2007-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8067376B2 (en) | Pharmaceutical compositions for transdermal delivery | |
| US11224565B2 (en) | N-acyldipeptide derivatives and their uses | |
| EP2875826B1 (en) | Composition for preventing or treating sepsis | |
| ES2492670T3 (en) | Peptide analogs of alpha-melanocyte stimulating hormone | |
| US8680059B2 (en) | Oligopeptide acetate and formulations thereof | |
| JPH08508299A (en) | Cytokine inhibitor | |
| EP2800758B1 (en) | N-acylpeptide derivatives and their uses | |
| Wang et al. | Preparation, purification, and characterization of a reversibly lipidized desmopressin with potentiated anti-diuretic activity | |
| KR101782569B1 (en) | Multifunctional skin penetration peptide with whitening, skin elasticity and wrinkle improvement ability | |
| CN102482323A (en) | Novel peptide and use thereof | |
| KR102091567B1 (en) | Pharmaceutical composition for prevention or treatment of brain injury comprising the osteopontin protein fragment as an active ingredient | |
| EP1372733B1 (en) | Pharmaceutical compositions of active polypeptides for enhanced pharmacological activity through oral and parenteral administration | |
| MXPA04011502A (en) | Compounds which can block the response to chemical substances or thermal stimuli or mediators of inflammation of nociceptors, production method thereof and compositions containing same. | |
| EP3925626A1 (en) | Lipopeptide conjugates and their salts, method of manufacture of lipopeptide conjugates and their salts, pharmaceutical composition comprising a lipopeptide conjugate and its salts for the treatment of chronic wounds | |
| JP2862140B2 (en) | Angiogenesis inhibitor | |
| KR20240041399A (en) | Novel peptide having anti-cancer activity and uses thereof | |
| WO2014075137A1 (en) | Peptides incorporating amino-substituted lactams for treatment of retinopathy | |
| CN114989259A (en) | Small molecular peptide Ped4 and application thereof | |
| KR20190138065A (en) | Fatty acid antifungal peptide and antifungal composition comprising the same | |
| US20100279944A1 (en) | Suppression and treatment of neuropathic pain | |
| WO2002072131A1 (en) | Remedies for liver diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 200580037223.4 Country of ref document: CN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020077009791 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007540252 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2005820534 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 3842/DELNP/2007 Country of ref document: IN |
|
| WWP | Wipo information: published in national office |
Ref document number: 2005820534 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 11667185 Country of ref document: US |